Clinical Trial Update: Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the combination of amplitude-modulated radiofrequency electromagnetic fields (AM RF EMF) with Fruquintinib for refractory…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Fruquintinib (fruquintinib)

Snippet

Sponsor: Barbara Ann Karmanos Cancer Institute | Conditions: Metastatic Colorectal Adenocarcinoma | Phase 2 | Status: RECRUITING